Mostrar el registro sencillo del ítem

dc.contributor.authorGarrido-Navas, M. Carmen (1)
dc.contributor.authorGarcía-Díaz, Abel
dc.contributor.authorMolina-Vallejo, María Pilar
dc.contributor.authorGonzález-Martínez, Coral
dc.contributor.authorAlcaide Lucena, Miriam
dc.contributor.authorCañas-García, Inés
dc.contributor.authorBayarri, Clara
dc.contributor.authorDelgado, Juan Ramón
dc.contributor.authorGonzález, Encarna
dc.contributor.authorLorente, José Antonio
dc.contributor.authorSerrano, M. José
dc.date2020-11
dc.date.accessioned2021-03-31T09:48:21Z
dc.date.available2021-03-31T09:48:21Z
dc.identifier.issn2072-6694
dc.identifier.urihttps://reunir.unir.net/handle/123456789/11158
dc.descriptionMost solid tumors share mutations in TP53 that is thus considered one of the main cancer driver genes. Mutations in TP53 occur very early during tumor development, so their identification helps in diagnosing cancer. Furthermore, knowing in advance the TP53 mutation status might help guiding targeted treatments against this gene. However, this analysis is mainly performed in tissue samples, that is, solid biopsies, being an invasive technique. Contrarily, liquid biopsies, consisting of the analysis of blood samples, are non-invasive, can be performed repeatedly, helping in monitoring the patient evolution, and might be useful in early stages when the tumor is not yet detected by other technologies. Here, we review the main studies conducted on two types of liquid biopsies: circulating tumor cells and cell-free DNA. We discuss the main findings regarding TP53 mutation analysis, the clinical utility of this information and some controversies arising from the study of liquid biopsies compared to tissue samples, and we finish by suggesting future directions within this field.es_ES
dc.description.abstractBeing minimally invasive and thus allowing repeated measures over time, liquid biopsies are taking over traditional solid biopsies in certain circumstances such as those for unreachable tumors, very early stages or treatment monitoring. However, regarding TP53 mutation status analysis, liquid biopsies have not yet substituted tissue samples, mainly due to the lack of concordance between the two types of biopsies. This needs to be examined in a study-dependent manner, taking into account the particular type of liquid biopsy analyzed, that is, circulating tumor cells (CTCs) or cell-free DNA (cfDNA), its involvement in the tumor biology and evolution and, finally, the technology used to analyze each biopsy type. Here, we review the main studies analyzing TP53 mutations in either CTCs or cfDNA in the three more prevalent solid tumors: breast, colon and lung cancers. We evaluate the correlation for mutation status between liquid biopsies and tumor tissue, suggesting possible sources of discrepancies, as well as evaluating the clinical utility of using liquid biopsies for the analysis of TP53 mutation status and the future actions that need to be undertaken to make liquid biopsy analysis a reality for the evaluation of TP53 mutations.es_ES
dc.language.isoenges_ES
dc.publisherCancerses_ES
dc.relation.ispartofseries;vol. 12, nº 11
dc.relation.urihttps://www.mdpi.com/2072-6694/12/11/3343es_ES
dc.rightsopenAccesses_ES
dc.subjectTP53 mutationses_ES
dc.subjectliquid biopsyes_ES
dc.subjectcfDNAes_ES
dc.subjectCTCes_ES
dc.subjecttissuees_ES
dc.subjectconcordancees_ES
dc.subjectJCRes_ES
dc.subjectScopuses_ES
dc.titleThe Polemic Diagnostic Role of TP53 Mutations in Liquid Biopsies from Breast, Colon and Lung Cancerses_ES
dc.typeArticulo Revista Indexadaes_ES
reunir.tag~ARIes_ES
dc.identifier.doihttps://doi.org/10.3390/cancers12113343


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem